MAY 07, 2020 6:16 AM PDT

New COVID-19 Vaccine Defends Monkeys Against Infection

WRITTEN BY: Tara Fernandez

Researchers from Beijing-based Sinovac Biotech have reported preliminary results of a study into the development of a vaccine against COVID-19. This is some of the first evidence of a vaccine showing efficacy in a primate experimental model (rhesus macaques) and provides hope for a global community anxiously awaiting countermeasures against the escalating pandemic.

Experts estimate that a clinically-available vaccine against SARS-CoV-2 could take 18 months or longer to develop, even at an accelerated pandemic pace. A new vaccine needs to be thoroughly tested for safety and efficacy in animals and humans prior to its commercialization. Before phase I testing, in which a small group of healthy volunteers receives the vaccine in development, vaccines are typically tested in non-human primates, which share physiological and disease process similarities with humans.

In Sinovac’s study, the vaccine testing protocol involved two doses of inactivated SARS-CoV-2, administered to a cohort of eight rhesus monkeys. The animals were allowed to develop a natural immune response to the inactivated virus over the course of three weeks. They were then exposed to live, unadulterated SARS-CoV-2 to test the protective capabilities of the vaccine treatment.

Encouragingly, none of the monkeys experienced the symptoms of severe infection, nor had any unwanted side-effects as a result of the shot. Meanwhile, the control animals developed pneumonia and high levels of circulating virus as a result of exposure to the coronavirus.

In response to these findings, Florian Krammer, a virologist based at the  Icahn School of Medicine at Mount Sinai said, “This is old school but it might work. What I like most is that many vaccine producers, also in lower–middle-income countries, could make such a vaccine.”

While promising, experts warn that preclinical validation of a new vaccine will involve much more work: larger testing cohorts to provide statistical significance and testing protection against viral strains that specifically infect humans and escape variant strains.

Sinovac has already launched phase I human trials of its vaccine in China to evaluate the safety and degree of protection in over 100 volunteers. If these clinical trials go as planned, phase II studies will kick off in mid-May in a larger group of over 1,000 individuals.

 


Source: Science.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
JUN 24, 2021
Immunology
Should We Rethink COVID Vaccine Recipes?
JUN 24, 2021
Should We Rethink COVID Vaccine Recipes?
In a study reported in the journal Cell, immunologists provide evidence for an Achilles’ heel in current COVI ...
JUN 28, 2021
Cell & Molecular Biology
Bringing Light to Extracellular Vesicles
JUN 28, 2021
Bringing Light to Extracellular Vesicles
Though originally thought of as strictly a waste disposal system, extracellular vesicles (EVs) have been shown to have m ...
JUN 29, 2021
Immunology
Speed Up qPCR Sample Preparation for SARS-CoV-2 Detection
JUN 29, 2021
Speed Up qPCR Sample Preparation for SARS-CoV-2 Detection
Amid the widespread outbreak of the COVID-19 caused by SARS-CoV-2, the development of test methods that can efficiently ...
JUN 28, 2021
Microbiology
Small Clinical Trial Suggests New Edible Cholera Vaccine Is Safe
JUN 28, 2021
Small Clinical Trial Suggests New Edible Cholera Vaccine Is Safe
According to WHO there have been six cholera pandemics since the pathogen emerged from the Ganges river delta sometime i ...
AUG 03, 2021
Health & Medicine
Viruses and Autoimmunity: What Pandemics Have Taught Us
AUG 03, 2021
Viruses and Autoimmunity: What Pandemics Have Taught Us
COVID-19 infections have given rise to COVID long haulers, people who had COVID and continue to have symptoms months aft ...
AUG 25, 2021
Cell & Molecular Biology
Sino Biological's Listing on the Shenzhen Stock Exchange
AUG 25, 2021
Sino Biological's Listing on the Shenzhen Stock Exchange
China, August 16, 2021 - Sino Biological, Inc. (“Sino Biological” or the “Company”), a biot ...
Loading Comments...